BridgeBio
Company
BridgeBio develops 3 assets, the furthest approved (infigratinib). Mostly small molecule acting on FGFR1, FGFR4 and fgfr3.
- 3
- Assets
- Furthest stage
- Approved
- 6
- Trials
- 2
- Signals
Pipeline
3Kinetic stabilizer of transthyretin tetramers preventing amyloidogenesis and fibril accumulation
Approved, Small molecule, TTR, cardiac amyloidosis (Phase 3), amyloid (Phase 3)
Inhibits FGFR tyrosine kinases, reducing excessive FGFR3 signaling that impairs bone growth in achondroplasia.
Approved, Small molecule, FGFR1, FGFR4, advanced cholangiocarcinoma (Phase 3), fgfr2 gene mutation (Phase 3)
Negative allosteric modulator (calcilytic) of the calcium-sensing receptor.
Phase 3, Small molecule, autosomal dominant hypocalcemia
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
31 asset, 3 trials
1 asset, 2 trials
1 asset, 1 trial
In the full profile
- Evidence behind the mechanisms7
- Trials7
- Signals11
- Similar companies6